DHAKA : After establishing themselves as a significant player in the Asian and African markets, Bangladeshi pharmaceutical companies are now expanding their footprints in the regulated markets. Medicine exports to the developed countries are on the rise. Medicine shipment to the US in FY 2020-21 was worth $15 million as opposed to $13.6 million in FY 2018-19. Denmark has emerged as the second largest export destination in developed world taking medicines worth $2.43 million in FY 2020- 21, a 14-fold rise from the previous year. Medicines worth $1.3 million was sent to Canada–62% growth from the past year. Export to the UK, Japan and Australia also grew. This growth in the advanced markets is partly attributed to regulatory approval from US (Food and Drug Administration), European and some other countries. Bangladesh’s capacity to produce high-quality drugs at affordable price as well as to make any generic version of drugs has also helped in this regard. This has brought a major change, technological and otherwise, in the local pharmaceutical industry.
- Plans underway to reduce electricity bills by generating 70% from renewable sources – State Minister
- President Wickremesinghe Highlights Middle-Income Country Challenges at 2023 SDG Summit
- Sri Lanka joins Treaty on Prohibition of Nuclear Weapons
- <strong>Education College admissions begin from October – Minister</strong>